The abstract outlines the evolving management of cardiogenic shock, highlighting the transition to using temporary mechanical circulatory support (t-MCS) like IABP, VA-ECMO, Impella, and ECPELLA, informed by advances in circulatory physiology. It emphasizes the importance of selecting appropriate t-MCS devices based on patient-specific conditions, shock stage, and risk, guided by hemodynamic monitoring and a multidisciplinary team approach.